Cyclooxygenase 2 Inhibitor Market

COX inhibitors are mostly antipyretic and analgesic anti-inflammatory drugs, namely non-steroidal anti-inflammatory drugs (NSAIDs). COX-2 has extremely low activity in normal tissue cells, and can only be produced in large quantities when induced. It mediates pain, inflammation, and fever by promoting PG synthesis. In general, multiple adverse effects of non-steroidal anti-inflammatory drugs are believed to be related to the inhibition of COX-1. As a result, COX-2 selective inhibitors have emerged.

Cyclooxygenase 2 Inhibitor Market contains market size and forecasts of Cyclooxygenase 2 Inhibitor in Global, including the following market information:

• Global Cyclooxygenase 2 Inhibitor Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

• The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
• Selective Cox 2 Inhibitor Segment to Reach $ Million by 2028, with a % CAGR in next six years.
• The global key manufacturers of Cyclooxygenase 2 Inhibitor include Pfizer, Bayer, Novartis, Merck, Sabinsa, Cadila Pharmaceuticals, Mylan, Teva Pharmaceutical and Alembic Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
• We surveyed the Cyclooxygenase 2 Inhibitor companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Global Cyclooxygenase 2 Inhibitor Market Segment Percentages, by Type, 2021 (%)

• Selective Cox 2 Inhibitor
• Non-Selective Cox 2 Inhibitor

Global Cyclooxygenase 2 Inhibitor Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Specialty Clinic
• Others

Global Cyclooxygenase 2 Inhibitor Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

The report also provides analysis of leading market participants including:

• Key companies Cyclooxygenase 2 Inhibitor revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Cyclooxygenase 2 Inhibitor revenues share in global market, 2021 (%)

• Pfizer
• Bayer
• Novartis
• Merck
• Sabinsa
• Cadila Pharmaceuticals
• Mylan
• Teva Pharmaceutical
• Alembic Pharmaceutical
• Aurobindo Pharma
• Cipla
• Torrent Pharmaceuticals